Table 3. Adverse events, treatment discontinuations and deaths.
|
1 Prior line |
⩾2 Prior lines |
|||
|---|---|---|---|---|
| Kd (n=232) | Vd (n=227) | Kd (n=231) | Vd (n=229) | |
| Any grade adverse event (n, %) | 226 (97.4) | 224 (98.7) | 229 (99.1) | 223 (97.4) |
| Grade ⩾3 adverse event (n, %) | 162 (69.8) | 145 (63.9) | 177 (76.6) | 160 (69.9) |
| Serious adverse event (n, %) | 102 (44.0) | 71 (31.3) | 122 (52.8) | 91 (39.7) |
| Adverse event leading to treatment discontinuation (n, %) | 40 (17.2) | 42 (18.5) | 52 (22.5) | 53 (23.1) |
| Adverse event leading to death (n, %) | 10 (4.3) | 7 (3.1) | 15 (6.5) | 14 (6.1) |
| Grade ⩾3 adverse events reported in ⩾5% of patients in any subgroup (n, %) | ||||
| Anemia | 30 (12.9) | 19 (8.4) | 37 (16.0) | 26 (11.4) |
| Diarrhea | 5 (2.2) | 11 (4.8) | 11 (4.8) | 23 (10.0) |
| Dyspnea | 12 (5.2) | 5 (2.2) | 13 (5.6) | 5 (2.2) |
| Fatigue | 14 (6.0) | 18 (7.9) | 11 (4.8) | 14 (6.1) |
| Hypertension | 24 (10.3) | 8 (3.5) | 17 (7.4) | 4 (1.7) |
| Lymphocyte count decreased | 13 (5.6) | 3 (1.3) | 13 (5.6) | 5 (2.2) |
| Peripheral neuropathy | 5 (2.2) | 10 (4.4) | 1 (0.4) | 14 (6.1) |
| Platelet count decreased | 8 (3.4) | 8 (3.5) | 9 (3.9) | 16 (7.0) |
| Pneumonia | 15 (6.5) | 14 (6.2) | 17 (7.4) | 22 (9.6) |
| Thrombocytopenia | 15 (6.5) | 18 (7.9) | 24 (10.4) | 25 (10.9) |
| Other select grade ⩾3 adverse events of interest (n, %) | ||||
| Cardiac failure | 5 (2.2) | 2 (0.9) | 5 (2.2) | 1 (0.4) |
| Lymphopenia | 10 (4.3) | 6 (2.6) | 10 (4.3) | 6 (2.6) |
| Neutropenia | 2 (0.9) | 4 (1.8) | 8 (3.5) | 6 (2.6) |
| Renal failure | 6 (2.6) | 2 (0.9) | 1 (0.4) | 0 |
Abbreviations: Kd, carfilzomib and dexamethasone; Vd, bortezomib and dexamethasone.